UltraSight™ Receives FDA Clearance

UltraSight™ Receives FDA Clearance to Expand Its AI-Guided Cardiac Echo Stewardship Platform Across Ultrasound Systems

Expanded authorization enables AI-guided FoCUS across devices—supporting consistent diagnostic-quality imaging and cardiology oversight across care settings.

BOSTON, MA, UNITED STATES, January 6, 2026 / UltraSight™, a leader in AI-guided cardiac imaging workflows, today announced FDA clearance to expand its Echo Stewardship Platform to support compatibility with additional ultrasound system types, including handheld, laptop, and cart-based systems. This expanded authorization helps health systems scale AI-guided focused cardiac ultrasound (FoCUS) using compatible ultrasound equipment they already own, without hardware replacement.

Read the Full Release